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Increased asthma severity is not only associated with enhanced recurrent hospitalization and mortality but also with
higher social costs.
Several cases of asthma are atopic in nature, with the trigger for acute asthma attacks and chronic worsening
of inflammation being allergens inducing an immune, IgE mediated response.
Anti-inflammatory treatments are effective for most of asthma patients, but there are subjects whose disease
is incompletely controlled by inhaled or systemic corticosteroids and these patients account for about 50% of
the healthcare costs of asthma.
Omalizumab is a biological engineered, humanized recombinant monoclonal anti-IgE antibody developed for
the treatment of allergic diseases and with clear efficacy in adolescent and adult patients with severe allergic
asthma. The anti-IgE antibody inhibits IgE functions blocking free serum IgE and inhibiting their binding to
cellular receptors. By reducing serum IgE levels and IgE receptor expression on inflammatory cells in the
context of allergic cascade, omalizumab has demonstrated to be a very useful treatment of atopic asthma,
improving quality of life of patients with severe persistent allergic asthma that is inadequately controlled by
currently available asthma medications. Several trials have demonstrated that this therapy is well tolerated and
significantly improves symptoms and disease control, reducing asthma exacerbations and the need to use
high dosage of inhaled corticosteroids.
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A body of evidence suggests that bronchial asthma and
other allergic diseases have become more common
worldwide in recent years and are recognized as a higly
prevalent health problem in the developed and develop-
ing world [1-6]. It is estimated that more than 50% of
asthma has an allergic background and about 50% of pa-
tients with severe asthma have allergic-atopic asthma
[2,6], although many previously published data demon-
strated that the severe phenotype is less frequent in
atopic adult-onset asthma [6-8].* Correspondence: gdamatomail@gmail.com
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It is well known that immunoglobulin E (IgE) antibodies,
Th2 derived cytokines and eosinophils play a major role
in the development of chronic airway inflammation,
which is observed even in subjects with mild disease
[9-12]. Airway inflammation plays a central role in the
pathogenesis of bronchial asthma and is associated with
an increase in airway responsiveness to several trigger
factors such as aeroallergens which induce bronchocon-
striction in atopic asthma patients, acting sometimes in
cooperation with other trigger factors such as viruses
and air pollution.
The development of inflammation in asthma involves
a complex array of several inflammatory mediators that
promote the recruitment and activation of various differ-
ent immune cells and regulate inflammatory cell traffick-
ing into the lungs.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cascades of intracellular signaling events that lead to re-
cruitment and activation of immune effector cells. The
inhibition of specific chemokines and receptors could
prevent the excessive recruitment of leukocytes to sites
of inflammation.
Elevated serum levels of specific IgE towards common
environmental allergens are a key component in the
pathogenesis of allergic asthma. IgE antibodies cause
chronic airway inflammation through effector cells such
as mastcells, basophils etc, activated via high-affinity
(FcεRI) or low-affinity (FcεRII) IgE receptors.
Current treatment for asthma suggested by Global Ini-
tiative for Asthma (GINA) guidelines includes several re-
liever and controller drugs, in particular corticosteroids
which reduce recruitment and activation of inflamma-
tory cells in the airways [13]. The available anti-asthma
treatments are effective for most of these patients.
However, there are asthmatic subjects who continue to
experience severe debilitating disease, since their bronco-
obstruction is incompletely controlled by inhaled or sys-
temic corticosteroids associated with other drugs such
as beta-2 agonist bronchodilators (short and long-
acting), antileukotrienes etc. Moreover, increased asthma
severity is not only associated with enhanced recurrent
hospitalisation and mortality within one year of initial hos-
pitalisation, but also with higher economical and social
costs [14].
IgE antibodies have been viewed as a target for im-
munological drug development in asthma, and a number
of strategies aimed at inhibiting its proinflammatory
action have been developed, despite an increase in re-
cent years in the availability of drugs used for asthma
therapy.
Mechanisms of action of omalizumab
Therapeutic anti-IgE antibodies, omalizumab, able to re-
duce free IgE levels avoiding the binding of IgE to Fcε RI
and the following development of allergic reaction
(crosslinking IgE and triggering degranulation and syntesis
of new-generated chemical mediators of IgE-sensitized
cells) are now widely used in the therapy of allergic bron-
chial asthma [15-34]. This anti-IgE monoclonal antibody
(omalizumab) binds IgE at the same site of Fc fragment
defined Cε3 domain as these antibodies bind Fcε RI and
FcεRII. Consequently, IgE effector functions are inhibited,
because the IgE binding to high-affinity receptors on IgE
effector cells is blocked, as well as the following activation
of mast cells and basophils [15-35]. In other words, in al-
lergic subjects omalizumab prevents the activation of cel-
lular response and the occurrence of asthma symptoms.
Omalizumab expresses a high degree of isotype specificity
and can neutralize serum free IgE without affecting other
antibody classes.Studies in patients with atopic asthma showed that
anti-IgE antibodies decrease serum IgE levels in a dose-
dependent manner and allergen-induced bronchocon-
striction during both the early and late-phase responses
to inhaled allergen [18-20].
Serum free IgE are rapidly reduced after omalizumab
administration and the expression of high-affinity recep-
tors is significantly reduced after three months treatment
[34]. Nevertheless, when omalizumab is withdrawn after
few months of therapy, the serum IgE levels return to
pretreatment values as well as the number of IgE recep-
tors on the basophils surface. This structural “involution”
reflects the trend of the symptoms related to the asthmatic
disease, leading patients to increase the dosage of standard
therapy [34-44].
Nopp et al. investigated the long-term efficacy of 6-
year-therapy with omalizumab in 18 patients with severe
IgE-mediated asthma 1 year [35] and 3 years [36] after
the withdrawal of omalizumab. In both cases the Au-
thors documented the stabilization of the asthma-related
symptoms, similar to that observed during the treatment
period with omalizumab, as well as the downregulation
of basophil allergen sensitivity.
The treatment with omalizumab should be potentiated
by specific immunotherapy, which is active by using
other immunologic mechanisms [45].
Recently, two studies investigated also the potential ef-
fects of omalizumab on airway remodeling. Hoshino
et al. [46] evaluated the effects of omalizumab on airway
wall thickening using Computed Tomography (CT).
Thirty patients with severe persistent asthma were ran-
domized to conventional therapy with (n = 14) or without
omalizumab (n = 16) for 16 weeks; the airway dimensions
were assessed by a validated CT technique. This study
showed that 16 weeks of treatment with omalizumab re-
duced airway wall thickness. The change in wall thickness
was associated with a marked reduction in sputum eosino-
phils, and improvement in pulmonary function and qual-
ity of life [46].
Riccio et al. [47] investigated the effect of long–term
anti-IgE on the thickening of the reticular basement mem-
brane (RBM) and eosinophil infiltration in bronchial biop-
sies from 11 patients with severe persistent allergic asthma
before and after (12 months) treatment with omalizumab.
The study showed that a substantial proportion of severe
asthmatics reduced the original bronchial RBM thickness
and eosinophil infiltration after one-year treatment with
anti-IgE [47].
Omalizumab in allergic asthma
In several clinical controlled trials omalizumab resulted
to be able to reduce asthma-related symptoms, to de-
crease corticosteroid use and to improve quality of life
of asthmatic patients [28-44,48-51] and some of these
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in patients with severe persistent asthma who are inad-
equately controlled by anti-asthma pharmacological ther-
apy (Additional file 1).
The anti-IgE approach to asthma treatment has several
advantages, including concomitant treatment of other IgE-
mediated diseases and a favorable side-effect profile regard-
less of the type of allergic sensitisation [28-34,41-44,48].
Omalizumab was shown not only to inhibit mast cell and
basophil responses but also to have inhibiting effect on the
inflammatory cells, such as eosinophils, T lymphocytes and
B lymphocytes which are fundamental to the chronic in-
flammatory response in allergic diseases such as asthma.
This background places anti-IgE therapy firmly in the do-
main of an anti-inflammatory treatment for chronic allergic
disease, with effect on multiple cell types.Omalizumab in severe asthma
Severe or refractory asthma remains a frustrating disease
for both patients and the clinicians treating them. Severe
asthma has been defined as persisting symptoms due
to asthma despite high-dose inhaled steroids (1,000 mcg
beclometasone dipropionate or equivalent) plus long-
acting beta-2 agonists, with the requirement for either
maintenance systemic steroids or at least two rescue
courses of steroids over 12 months and despite trials
of add-ons such as leukotriene-receptor antagonist or
theophylline.
The Global Initiative for Asthma (GINA) [13] guidelines
for patients with severe persistent asthma (step 5 therapy)
recommend the use of high-dose inhaled corticosteroids
plus a long-acting beta-2 agonist (LABA), and, if required,
one more additional controller. Currently several studies
showed benefits of omalizumab as add-on therapy in pa-
tients with severe persistent asthma who are inadequately
controlled, despite best available therapy.
The INNOVATE (INvestigatioN of Omalizumab in se-
Vere Asthma TrEatment) study was specifically designed
to evaluate the efficacy and safety of add-on therapy with
omalizumab in this difficult asthma population [43].
In the INNOVATE trial were enrolled patients aged
12-75 years with severe persistent allergic asthma (GINA
step 3 or 4 clinical features despite step 4 therapy). The
primary efficacy variable was the rate of clinically signifi-
cant asthma exacerbations (defined as a worsening of
asthma symptoms requiring treatment with systemic cor-
ticosteroids). A total of 419 patients were included in the
efficacy analyses (omalizumab, n = 209; placebo, n = 210).
The rate of clinically significant asthma exacerbations,
after adjusting for an observed imbalance in asthma
exacerbation history prior to randomization, was signifi-
cantly reduced by 26.2% with omalizumab versus placebo
(0.68 and 0.91, respectively; p = 0.042).Compared with placebo, treatment with omalizumab
significantly reduced the rate of severe asthma exacer-
bations (0.24 vs 0.48, p = 0.002) and the rate of total
emergency visits for asthma (0.24 vs 0.43, p = 0.038).
Significantly greater improvements were achieved with
omalizumab compared with placebo in Asthma Quality
of Life Questionnaire (AQLQ) scores (overall and indi-
vidual domains), with a significantly greater proportion
of patients receiving omalizumab achieving a clinically
meaningful (> 0.5-point) improvement from baseline
compared with placebo recipients (61% and 48%, respect-
ively; p = 0.008).
Several “real life” studies confirmed the efficacy and
tolerability of omalizumab in severe persistent allergic
asthma patients.
One trial was an observational study performed in France
[44]. The second one was a prospective post-marketing
surveillance trial that evaluated the efficacy and toler-
ability of omalizumab in real-life in Germany [48], and
the third study was a prospective multicenter real-life study
conducted in Belgium, the PERSIST study [49], the fourth
was a small questionnaire-based observational study in 65
patients in the UK, who had continued with omalizumab
therapy beyond 16 weeks, conducted by Niven et al. [50].
In the first study, the authors evaluated 154 patients.
The analysis performed during the treatment period and
compared to the previous year, showed that patients
with a follow up of at least 5 months experienced 62%
fewer exacerbations requiring oral corticosteroids, 65%
fewer emergency department visits and 29% fewer hospi-
talisations per year. Korn and co-workers [48] reported
the results of the observation of 280 patients followed up
for 6 months. After 6 months of specific anti-IgE therapy,
omalizumab was demonstrated to reduce the daily (−76%)
and nocturnal symptoms (−84%), exacerbations (−82%),
unscheduled medical assistance (−81%), hospitalisations
(−78%) and increase quality of life (Mini-AQLQ: score in-
crease from 2.9 to 4.5). Overall, efficacy of omalizumab
was rated as excellent or good by the majority of physi-
cians (82%) and patients (86%).
In the PERSIST Study Brusselle and co-workers [49]
evaluated the 15- and 52-week effectiveness of add-on
omalizumab treatment in 158 enrolled subjects. After 16
weeks of therapy, a good/excellent global evaluation of
treatment effectiveness (GETE) was achieved by > 82%
(p < 0.001), the total AQLQ scores improved in > 82%
by > 0.5 points (p < 0.001) and > 91% of the subjects
were exacerbation-free. At 52 weeks, the same results
were achieved by > 72% (p < 0.001), > 84% (p < 0.001)
and > 65% (p < 0.001), respectively. In addition, a signifi-
cant reduction in healthcare utilization compared the year
prior to treatment was observed.
Niven et al. [50] found that out of 33 patients taking
oral corticosteroid at baseline, 18 (54.5%) had reduced
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corticosteroid altogether. The mean relative reduction in
oral corticosteroid dose from baseline was 49% (22.6–
11.6 mg, prednisolone equivalent).
All these studies showed that anti-IgE treatment has a
reassuring safety profile. It is tolerated, and its overall ad-
verse event profile is similar to that of placebo (Additional
file 2).
Safety and tolerability
In a review Corren and co-workers [51] evaluated the
safety of omalizumab in a pooled analysis of data from
15 randomized multicentric studies involving more than
7,500 patients (adults, adolescents and children). All pa-
tients suffered from severe persistent allergic asthma
and the majority of them received omalizumab for al-
most 24 weeks at the dose of 150-300 mg every four
weeks or 225, 300 or 375 mg every two weeks. In all
studies the number of adverse events (AEs) was similar
between groups and the majority of AEs were mild or
moderate. The most frequent AE observed in both groups
was nasopharyngitis; no difference indicative of omalizu-
mab specific tossicity was detected between groups. The
only AE with > 2% difference between groups was sinus-
itis, observed in 10.1% of patients treated with omalizu-
mab and in 12.2% in the placebo groups. The assessment
of laboratory parameters did not show any significant
effect of omalizumab on blood cells counts, renal and
liver function; however, no data exist about patients
with previous renal or hepatic impairment treated with
omalizumab, thus caution should be used in administering
the drug in these sets of patients. This review confirmed
that add-on omalizumab is an effective and well tolerated
treatment in patients with severe IgE-mediated asthma,
and its cost-effectiveness is similar to other chronic dis-
ease biologics. Furthermore, the same authors highlight
that, despite its cost, omalizumab used as an add-on ther-
apy in this setting of patients improves quality-adjusted
survival (QALYs) at an increase in direct medical costs,
and that this value is directly related to the duration of
the therapy.
Several other studies have been recently published. In
the trial of Busse et al. [52] research has underscored the
effects of exposure and sensitization to allergens on the
severity of asthma in children and when added to a regi-
men of guidelines-based therapy for inner-city children,
adolescents, and young adults, omalizumab further im-
proved asthma control, nearly eliminated seasonal peaks
in exacerbations, and reduced the need for other medi-
cations to control asthma.
In the study of Braunstahl et al. [53] by physician’s
GETE, 69.9% of patients were responders to omalizumab
after 16 weeks. The proportion of patients with no clin-
ically significant exacerbations increased from 6.8%during the 12 month pre-treatment period to 54.1% and
67.3% at months 12 and 24, respectively. Symptoms and
rescue medication use at month 24 were reduced by >
50% from baseline. Maintenance oral corticosteroids use
was lower at month 24 (14.2%) compared with month
12 (16.1%) and baseline (28.6%). Overall, the results from
eXpeRience registry indicate that omalizumab was associ-
ated with improvements in outcomes in patients with
uncontrolled persistent allergic asthma and that these
improvements were consistent with the results of clinical
trials. However, omalizumab is effective in treating severe
asthma also in patients with severe cardiovascular compli-
cations [54].
Omalizumab in other respiratory and non-respiratory
diseases
In addition to asthma, omalizumab has been investigated in
treatment of various other diseases. However, there is sugges-
tion for use of omalizumab also in intrinsic asthma [54-60].
The efficacy of omalizumab was also observed in patients
with severe occupational asthma, regardless of whether the
causative agent was high molecular weight (HMW) or low
molecular weight (LMW) [61]. This is particularly relevant
for patients who are unable to avoid allergen exposure in
their place of work.
Conclusions
Results of several large randomized trials have established
omalizumab as an effective and well tolerated treatment
for use as add-on therapy in patients with severe persist-
ent allergic asthma. Several trials have demonstrated that
this therapy is well tolerated and significantly improves
symptoms and disease control, reducing asthma exacerba-
tions and improving quality of life of asthma patients.
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